Terlipressin Peptide: Terlivaz, Glypressin, Uses and Safety Limits
Terlipressin peptide guide covering vasopressin V1 receptor biology, the Terlivaz hepatorenal syndrome label, variceal bleeding evidence and respiratory and ischemic safety limits.
Terlipressin is a peptide medicine with a very different evidence profile from research-market or wellness peptides. It is a synthetic analog of the hormone vasopressin, sold in the United States as Terlivaz and in many other countries as Glypressin and similar brands. It is a hospital drug given by injection, not a self-administered protocol.
The defining feature of terlipressin is that it is a potent vasoconstrictor. That property is the source of both its benefit and its danger. It can raise blood pressure and redirect blood flow in ways that help selected patients with advanced liver disease, but the same action can starve tissues of blood supply and impair breathing. Context, monitoring and patient selection are everything.
This guide is educational and not medical advice. Terlipressin is a prescription medicine used in supervised hospital settings. It should be started, monitored, changed or stopped only through qualified medical care. For background, see what peptides are and the peptide half-life guide.
Terlipressin At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic vasopressin analog peptide and a prodrug for lysine-vasopressin. |
| US brand | Terlivaz (terlipressin), FDA approved in 2022. |
| Other brands | Glypressin and related names outside the US. |
| Main effect | Splanchnic vasoconstriction that lowers portal pressure and raises arterial pressure. |
| Main receptor | Vasopressin V1 receptor, with roughly twice the V1-over-V2 selectivity of vasopressin. |
| US indication | Improving kidney function in adults with hepatorenal syndrome and rapid kidney decline. |
| Route | Intravenous bolus injection in a hospital setting. |
| Main safety frame | Boxed warning for serious or fatal respiratory failure, plus ischemic risk. |
How A Vasopressin Analog Lowers Portal Pressure
Native vasopressin, also called antidiuretic hormone, acts on several receptor types. V1A receptors on vascular smooth muscle drive vasoconstriction, V2 receptors in the kidney drive water retention, and V1B (V3) receptors sit in the pituitary. Vasopressin itself is short-acting and relatively nonselective, which limits its usefulness as a sustained vasoconstrictor.
Terlipressin is engineered to be different. According to the Terlivaz prescribing information and pharmacology reviews, it is more selective for V1 receptors than V2 receptors, with V1 selectivity roughly twice that of vasopressin. It is also a prodrug. Tissue peptidases slowly cleave its N-terminal glycyl residues to release lysine-vasopressin, the active metabolite. This slow-release design gives a longer, steadier effect than a vasopressin infusion, which is why terlipressin can be given as intermittent boluses rather than a continuous drip.
The therapeutic logic in liver disease follows from this. In advanced cirrhosis, the splanchnic circulation (the blood vessels supplying the gut) becomes abnormally dilated. That dilation drops effective arterial blood volume, triggers compensatory systems that constrict the kidney's blood vessels, and can cause hepatorenal syndrome. By constricting the splanchnic vessels, terlipressin reduces portal hypertension and restores effective arterial volume and mean arterial pressure, which can improve renal blood flow.
Approved Use: Hepatorenal Syndrome
The FDA approved terlipressin as Terlivaz on September 14, 2022, making it the first FDA-approved drug to improve kidney function in adults with hepatorenal syndrome with a rapid reduction in kidney function. The applicant was Mallinckrodt. Outside the United States, terlipressin had decades of use under brands such as Glypressin, and European guidelines recommended terlipressin plus albumin as first-line therapy for hepatorenal syndrome before the US approval.
The pivotal evidence is the CONFIRM trial (NCT02770716), published in the New England Journal of Medicine in 2021. CONFIRM randomized 300 adults with cirrhosis and type 1 hepatorenal syndrome at North American centers in a 2:1 ratio to terlipressin or placebo, with albumin strongly recommended in both arms. Verified HRS reversal, defined by two consecutive low serum creatinine values plus survival free of kidney replacement therapy, occurred in 32% of the terlipressin group versus 17% of placebo (the trial reported P = .006 for this outcome).
The honest reading is that the kidney-function benefit is real but partial. Most patients did not achieve verified reversal even on terlipressin. CONFIRM also reported 90-day mortality of 51% with terlipressin and 45% with placebo, a difference that was not a mortality benefit, and it surfaced the respiratory and ischemic harms that now anchor the label. The Terlivaz label also adds a limitation of use: patients with a serum creatinine above 5 mg/dL are unlikely to benefit.
| Source | What it supports | Important limit |
|---|---|---|
| Terlivaz FDA label | Improving kidney function in adults with HRS and rapid renal decline. | Boxed warning for respiratory failure; serum creatinine over 5 mg/dL unlikely to benefit. |
| CONFIRM trial (NEJM 2021) | 32% verified HRS reversal vs 17% placebo. | No mortality benefit; high serious adverse event burden. |
| European guidelines/history | Terlipressin plus albumin as first-line HRS therapy. | Reflects practice outside the US label framework. |
Off-Label And International Use: Variceal Bleeding
Beyond hepatorenal syndrome, terlipressin has a long history in acute bleeding from esophageal varices, a life-threatening complication of portal hypertension. This is not the US-approved indication, but it is a major international use and is well studied. A systematic review and meta-analysis of randomized controlled trials reported that, compared with no vasoactive drug, terlipressin improved control of bleeding and reduced mortality, while head-to-head data versus agents such as octreotide and somatostatin generally showed broadly comparable efficacy.
The mechanism is the same: splanchnic vasoconstriction lowers portal inflow and pressure, which helps stop variceal bleeding. The takeaway for readers is that terlipressin's vasoconstrictor identity is consistent across its uses, but the strength of the evidence and the regulatory status differ by indication and country.
Safety Limits
Terlipressin safety follows directly from its mechanism. A drug that constricts blood vessels everywhere can reduce perfusion to organs that need it, and it can shift fluid in ways that flood the lungs. The Terlivaz label leads with a boxed warning, and several risks are serious.
| Safety issue | Why it matters |
|---|---|
| Respiratory failure (boxed warning) | Serious or fatal respiratory failure occurred more often than placebo; patients with volume overload or ACLF Grade 3 are at higher risk. |
| Hypoxia contraindication | Do not initiate in patients with hypoxia (for example SpO2 below 90%) until oxygenation improves. |
| Ischemia | Risk of ischemia affecting cardiac, cerebrovascular, peripheral and mesenteric circulation; ongoing ischemia is a contraindication. |
| Volume overload | Fluid shifts can worsen pulmonary edema; albumin co-administration must be managed carefully. |
| Limited benefit population | Serum creatinine above 5 mg/dL is unlikely to benefit, and treatment may affect liver transplant eligibility. |
| Hyponatremia and electrolyte shifts | Residual V2 activity and fluid changes can disturb sodium and fluid balance. |
These are not abstract footnotes. The boxed warning and the contraindications exist because the trial population, who were critically ill with advanced liver disease, experienced these harms at meaningful rates. Terlipressin is given where respiratory status, oxygenation, fluid balance and signs of ischemia can be monitored continuously.
How To Evaluate A Terlipressin Claim
Because terlipressin is a peptide, it sometimes gets grouped with research or wellness peptides online. It does not belong there. Use a few questions to keep claims honest.
First, which use is being discussed: the FDA-approved hepatorenal syndrome indication, off-label variceal bleeding, or something unsupported? Second, does the source mention the boxed warning for respiratory failure and the ischemia risks, or does it present only the benefit? Third, does it acknowledge that CONFIRM showed partial kidney-function reversal and no mortality benefit? Fourth, is anyone implying this is a self-injectable peptide? It is a hospital intravenous drug, not a home protocol.
It also helps to compare terlipressin with other targeted peptides to see how specific these drugs are. Octreotide reduces splanchnic blood flow through somatostatin receptors rather than vasopressin receptors. Icatibant blocks the bradykinin B2 receptor for a completely different condition. Oxytocin is a structurally related nonapeptide hormone but acts on its own receptor and clinical context. Each is a distinct molecule with a distinct label, which is exactly why "peptide" alone tells you very little about safety.
Bottom Line
Terlipressin is a real, FDA-approved peptide medicine with genuine clinical value. As Terlivaz, it is the first US-approved treatment to improve kidney function in adults with hepatorenal syndrome, and as Glypressin and related brands it has a long international record in variceal bleeding. Its vasopressin V1 receptor agonism and prodrug design give it durable, targeted vasoconstriction that lowers portal pressure and supports arterial perfusion.
The same mechanism sets hard limits. The evidence in hepatorenal syndrome shows a partial kidney benefit without a mortality advantage, and the label carries a boxed warning for serious or fatal respiratory failure alongside ischemic and volume-overload risks. Terlipressin is a supervised hospital drug for specific, severe conditions, not a general-purpose or self-administered peptide.
References
U.S. Food and Drug Administration. FDA approves treatment to improve kidney function in adults with hepatorenal syndrome.
DailyMed. TERLIVAZ (terlipressin) injection prescribing information.
Wong F, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome (CONFIRM). N Engl J Med 2021;384:818-828.
ClinicalTrials.gov. Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome Type 1 (CONFIRM, NCT02770716).
Allgaier J, et al. Formulary Drug Reviews: Terlipressin. PMC10977064.
Department of Veterans Affairs. Terlipressin (TERLIVAZ) in Hepatorenal Syndrome National Drug Monograph (2023).
Zhou X, et al. Terlipressin for the treatment of acute variceal bleeding: a systematic review and meta-analysis of randomized controlled trials.
Kulkarni AV, et al. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int 2020.
Kam PCA, et al. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004.